Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D
Mol Cancer. 2025; 24(1):69.
PMID: 40050933
PMC: 11887392.
DOI: 10.1186/s12943-025-02249-2.
Shrestha P, Ghoreyshi Z, George J
Sci Rep. 2025; 15(1):7308.
PMID: 40025156
PMC: 11873109.
DOI: 10.1038/s41598-025-91396-z.
Jiramonai L, Liang X, Zhu M
Pharmaceutics. 2025; 17(2).
PMID: 40006624
PMC: 11859549.
DOI: 10.3390/pharmaceutics17020257.
Toghraie F, Bayat M, Hosseini M, Ramezani A
Cell Oncol (Dordr). 2025; .
PMID: 39998754
DOI: 10.1007/s13402-025-01051-y.
Xu Y, Kang K, Coakley B, Eisenstein S, Parveen A, Mai S
EMBO J. 2025; .
PMID: 39948411
DOI: 10.1038/s44318-024-00330-y.
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy.
Henick B, Taylor A, Nakagawa H, Wong K, Diehl J, Rustgi A
Cancer Cell. 2025; 43(2):178-194.
PMID: 39933897
PMC: 11875029.
DOI: 10.1016/j.ccell.2025.01.003.
Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma.
Oura K, Morishita A, Tadokoro T, Fujita K, Tani J, Kobara H
Int J Mol Sci. 2025; 25(24.
PMID: 39769351
PMC: 11679663.
DOI: 10.3390/ijms252413590.
Immune Cell Profiling Reveals a Common Pattern in Premetastatic Niche Formation Across Various Cancer Types.
Sugiyama S, Yumimoto K, Nakayama K
Cancer Med. 2024; 14(1):e70557.
PMID: 39740041
PMC: 11683674.
DOI: 10.1002/cam4.70557.
MDSC: a new potential breakthrough in CAR-T therapy for solid tumors.
Mohamady Farouk Abdalsalam N, Ibrahim A, Saliu M, Liu T, Wan X, Yan D
Cell Commun Signal. 2024; 22(1):612.
PMID: 39702149
PMC: 11660884.
DOI: 10.1186/s12964-024-01995-y.
Identification and validation of ion channels-related mRNA prognostic signature for glioblastomas.
Huang C, Yu X, Zhou Y, Bao W
Medicine (Baltimore). 2024; 103(48):e40736.
PMID: 39612412
PMC: 11608677.
DOI: 10.1097/MD.0000000000040736.
Insights into CSF-1R Expression in the Tumor Microenvironment.
Tomassetti C, Insinga G, Gimigliano F, Morrione A, Giordano A, Giurisato E
Biomedicines. 2024; 12(10).
PMID: 39457693
PMC: 11504891.
DOI: 10.3390/biomedicines12102381.
Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment.
Zhang H, Li S, Wang D, Liu S, Xiao T, Gu W
Biomark Res. 2024; 12(1):96.
PMID: 39227970
PMC: 11373140.
DOI: 10.1186/s40364-024-00646-1.
Proliferation of MDSCs may indicate a lower T cell immune response in schistosomiasis japonica.
Peng B, Luo Y, Xie S, Zhuang Q, Li J, Zhang P
Parasite. 2024; 31:52.
PMID: 39212529
PMC: 11363901.
DOI: 10.1051/parasite/2024050.
Revisiting the role of hypoxia-inducible factors and nuclear factor erythroid 2-related factor 2 in regulating macrophage inflammation and metabolism.
Ting K
Front Cell Infect Microbiol. 2024; 14:1403915.
PMID: 39119289
PMC: 11306205.
DOI: 10.3389/fcimb.2024.1403915.
Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
Montoya M, Collins S, Chuntova P, Patel T, Nejo T, Yamamichi A
Neuro Oncol. 2024; 26(12):2272-2287.
PMID: 39115195
PMC: 11630541.
DOI: 10.1093/neuonc/noae149.
Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review).
Zeng W, Liu H, Mao Y, Jiang S, Yi H, Zhang Z
Int J Oncol. 2024; 65(3).
PMID: 39054950
PMC: 11299769.
DOI: 10.3892/ijo.2024.5673.
Emergency myelopoiesis in solid cancers.
Aliazis K, Yenyuwadee S, Phikulsod P, Boussiotis V
Br J Haematol. 2024; 205(3):798-811.
PMID: 39044285
PMC: 11610632.
DOI: 10.1111/bjh.19656.
MDSCs use a complex molecular network to suppress T-cell immunity in a pulmonary model of fungal infection.
Kaminski V, Borges B, Santos B, Preite N, Calich V, Loures F
Front Cell Infect Microbiol. 2024; 14:1392744.
PMID: 39035356
PMC: 11257977.
DOI: 10.3389/fcimb.2024.1392744.
Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression.
Wang Y, Li J, Nakahata S, Iha H
Int J Mol Sci. 2024; 25(13).
PMID: 39000453
PMC: 11242872.
DOI: 10.3390/ijms25137346.
Current and future immunotherapeutic approaches in pancreatic cancer treatment.
Farhangnia P, Khorramdelazad H, Nickho H, Delbandi A
J Hematol Oncol. 2024; 17(1):40.
PMID: 38835055
PMC: 11151541.
DOI: 10.1186/s13045-024-01561-6.